Zine News

Medexus Reports Health Quality Ontario Recommends Gliolan® for Public Reimbursement

MONTREAL, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that Health Quality Ontario, under the guidance of the Ontario Health Technology Advisory Committee, has recommended public  funding of Gliolan® (5-aminolevulinic acid hydrochloride) for guiding maximal surgical resection of high-grade gliomas in adults, conditional on Health Canada approval.  Gliolan® assists neurosurgeons to better visualize and more completely remove malignant brain tumors (gliomas) by causing them to become fluorescent and glow during surgery.

Publicaciones relacionadas

Botón volver arriba
Cerrar